We empower people with innovative treatment solutions

 

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 

 

Development pipeline targeting large medical needs

 

 

AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products

Key News

SEPTEMBER 26, 2023
Our skilled RnD team in Uppsala, Sweden, is looking for a master student to write a thesis paper on drug delivery. 

To read all NEWS go to Media in the top menu 

Key financial figures

Group net revenue

634 MSEK
Last Twelve Months, Q322-Q223

Group EBITDA

-121 MSEK
Last Twelve Months, Q322-Q223

US Pharma segment EBIT

293 MSEK
Last Twelve Months, Q322-Q223

Cash position

251 MSEK
Q223
To read all NEWS go to Media in the top menu